Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung17: Datopotamab deruxtecan vs docetaxel in previously treated TROP2-positive non-squamous NSCLC
jRCT2031250462Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Started Oct 2025; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250462.